Hypertrophic cardiomyopathy (HCM) is a common yet complex genetic heart disorder, which is characterized by hypertrophy of the heart muscle, most commonly affecting the left ventricle. Mutations in genes encoding or related to cardiac sarcomere proteins, such as MYBPC3, MYH7, and TNNT2, can be introduced into animals via gene editing. These mutations disrupt the normal structure and function of the heart muscle, leading to the development of HCM. GemPharmatech has developed Myh6 R404Q and Mybpc3 KO mouse models which express hypertrophic cardiomyopathy phenotypes and can provide drug efficacy evaluation services based on these models.
